The Takeaway: Jason Kelly thinks the real biotech breakthrough isn’t better models—it’s autonomous labs that let AI run experiments nonstop.
- Biology is still mostly done like manual labor: brilliant PhDs moving liquids by hand, with expensive lab overhead swallowing most research budgets.
- The big shift is from designing biology to accelerating the test cycle; Kelly says AI doesn’t need to be more creative than scientists, just better at running the logic loop.
- In Ginkgo’s OpenAI project, a reasoning model running a robotic lab beat the state of the art on cell-free protein synthesis, then improved results by 40% after six rounds.
Kelly, founder and CEO of Ginkgo Bioworks, has been chasing the same mission since 2008: make biology easier to engineer. He bootstrapped for years, then found traction after YC in 2014, but the core idea never changed. DNA is code, cells are programmable, and the bottleneck has always been the painfully slow “compile/debug” cycle of biology.
What changed is where he’s placing the bet. He’s moved away from trying to solve the hardest design problem directly and toward the lab itself. His argument is blunt: “It was that it could run experiments.” The model didn’t need genius-level intuition; it needed access to a robotic lab, fast feedback, and the ability to share raw experimental data across many hypotheses every day.
That’s why he sees autonomous labs as a structural shift, not a tooling upgrade. Today’s science is fragmented, under-shared, and dominated by overhead. His vision is a fleet of AI scientists running 24/7, learning from each other in real time, and turning research into a much more efficient, usage-based system. For Kelly, that means biotech isn’t just getting digitized—it’s about to be reorganized.